drugset / Trial / NCT05925166
Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ Fusion Protein in the Treatment of Acute Gout
RandomizedParallel-groupOpen-labelTreatment
Summary
The goal of this study is to evaluate the efficacy and safety of Recombinant Human Tumor necrosis Factor-α Receptor Ⅱ Fusion Protein （rhTNFR-Fc）in the treatment of patients with acute Gout.
Timeline
- Start
- 2020-09-01
- Primary completion
- 2025-07-01
- Completion
- 2026-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Methylprednisolone | Other / unclassified | 20 mg | Intravenous |
| Subject | rhTNFR-Fc | Protein / enzyme biologic | 25 mg | Subcutaneous |